Literature DB >> 1655317

A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.

C A O'Donnell1, W L Chan.   

Abstract

The ability of non-glycosylated precursor glycoprotein B (pgB) to induce T cell responses in herpes simplex virus (HSV) infected mice was compared with fully glycosylated glycoprotein B (gB) and with whole virus. pgB was as effective as gB in priming for virus- and glycoprotein-specific T cells. pgB could also re-stimulate virus or glycoprotein primed cells in vitro as efficiently as gB. In addition, priming with pgB protected mice against a lethal challenge with HSV type 1 (HSV-1) and could induce the early in vivo production of IL-2 and IL-3 in infected mice. In all of these responses, pgB was as effective as gB. Thus, the carbohydrate side chains on gB do not appear to be necessary for T cell recognition of this protein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655317      PMCID: PMC1554163          DOI: 10.1111/j.1365-2249.1991.tb05769.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

Review 1.  The structure of T-cell epitopes.

Authors:  A M Livingstone; C G Fathman
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

2.  Kinetics of expression of herpes simplex virus type 1-specific glycoprotein species on the surfaces of infected murine, simian, and human cells: flow cytometric analysis.

Authors:  S R Jennings; P A Lippe; K J Pauza; P G Spear; L Pereira; S S Tevethia
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

3.  The functions of oligosaccharide chains associated with influenza C viral glycoproteins. II. The role of carbohydrates in the antigenic properties of influenza C viral glycoproteins.

Authors:  S Hongo; K Sugawara; M Homma; K Nakamura
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

4.  T cells recognize both conformational and cryptic determinants on the insulin molecule.

Authors:  J W Thomas; H George-Gattner; W Danho
Journal:  Eur J Immunol       Date:  1989-03       Impact factor: 5.532

5.  Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells.

Authors:  C Pachl; R L Burke; L L Stuve; L Sanchez-Pescador; G Van Nest; F Masiarz; D Dina
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

6.  Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.

Authors:  K J Cremer; M Mackett; C Wohlenberg; A L Notkins; B Moss
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

7.  Antigenic and biochemical analysis of gB of herpes simplex virus type 1 and type 2 and of cross-reacting glycoproteins induced by bovine mammillitis virus and equine herpesvirus type 1.

Authors:  B W Snowden; P R Kinchington; K L Powell; I W Halliburton
Journal:  J Gen Virol       Date:  1985-02       Impact factor: 3.891

8.  Interleukin-3 protects mice from acute herpes simplex virus infection.

Authors:  W L Chan; H J Ziltener; F Y Liew
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

9.  Mechanism of recognition of herpes simplex virus type 1-infected cells by natural killer cells.

Authors:  J A López-Guerrero; B Alarcón; M Fresno
Journal:  J Gen Virol       Date:  1988-11       Impact factor: 3.891

10.  Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.

Authors:  W L Chan; M L Lukig; F Y Liew
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

View more
  1 in total

1.  Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.

Authors:  Elisabeth Sievers; Jürgen Neumann; Martin Raftery; Günther SchOnrich; Anna Maria Eis-Hübinger; Norbert Koch
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.